Table 1.
Trials with Small Molecule Inhibitors Targeting Genomic Pathway Alterations.
| Drug | Combination | Status | Clinical Trial ID |
|---|---|---|---|
| PI3K Inhibitors | |||
| BKM120(Novartis, USA) | Cetuximab | Phase I/II | NCT01816984 |
| Single agent | Phase II | NCT01737450 | |
| Cisplatin | Phase I | NCT02113878 | |
| PX‐866(Oncothyreon, USA) | Cetuximab | Phase I/II | NCT01252628 |
| Docetaxel | Phase I/II | NCT01204099 | |
| BYL719(Novartis, USA) | Cetuximab | Phase I/II | NCT01602315 |
| Single agent | Phase II | NCT02145312 | |
| Paclitaxel | Phase I | NCT02051751 | |
| Cisplatin | Phase I | NCT02537223 | |
| Single agent | Phase II | NCT02145312 | |
| Copanlisib | Cetuximab | Phase I/II | NCT02822482 |
| SF1126 | Single agent | Phase II | NCT02644122 |
| mTOR inhibitors | |||
| Everolimus(Novartis) | Single agent | Phase II | NCT01051791 |
| Single agent | Phase II | NCT01133678 | |
| Carboplatin, Cetuximab | Phase I/II | NCT01283334 | |
| Carboplatin, paclitaxel | Phase I/II | NCT01333085 | |
| Cetuximab | Phase I | NCT01637194 | |
| Erlotinib | Phase II | NCT00942734 | |
| Rapamycin(pfizer,USA) | Single agent | Phase I/II | NCT01195922 |
| Temsirolimus(Pfizer) | Single agent | Phase II | NCT01172769 |
| Cetuximab | Phase II | NCT01256385 | |
| Carboplatin, paclitaxel | Phase I/II | NCT01016769 | |
| Cetuximab | Phase I | NCT02215720 | |
| PI3K/mTOR Dual Inhibitors | |||
| BEZ235(Novartis,USA) | Everolimus | Phase I | NCT01508104 |
| PF04691502(pfizer,USA) | Single agent | Phase I | NCT00927823 |
| PF05212384(Pfizer,USA) | Docetaxel, Cisplatin, Dacomitinib | Phase I | NCT01920061 |
| PD‐901, Irinotecan | Phase I | NCT01347866 | |
| SAR245409(sanofi, USA) | Pimasertib | Phase I | NCT01390818 |
| PQR309 | Single agent | Phase I | NCT02483858 |
| Akt Inhibitors | |||
| MK2206(Merck, USA) | Single agent | Phase II | NCT01349933 |
| MEK inhibitors | |||
| PD‐0325901 | PF‐05212384 | Phase I | NCT01347866 |
| CDK Inhibitor | |||
| Palbociclib | Cetuximab | Phase I/II | NCT03024489 |
| Gedatolisib | Phase I | NCT03065062 | |
| P276–00 | Single agent | Phase I/II | NCT00899054 |
| Single agent | Phase II | NCT00824343 | |
| Smac Mimetics/IAP antagonists | |||
| Debio1143 | Cisplatin | Phase I/II | NCT02022098 |
| Single agent | Phase I | NCT01078649 | |
| GDC0917 | Single agent | Phase I | NCT01908413 |
| Single agent | Phase I | NCT01226277 | |
| LCL‐161 | Paclitaxel | Phase I | NCT01968915 |
| Paclitaxel | Phase I | NCT01240655 | |
| Single agent | Phase I | NCT01098838 | |
| GDC0152 | Single agent | Phase I/II | NCT00977067 |
| Birinapant | Chemotherapy | Phase I/II | NCT01188499 |
| Single agent | Phase I | NCT00993239 | |
| HG5–1029 | Single agent | Phase I | NCT00708006 |
| ASTX‐660 | Single agent | Phase I/II | NCT02503423 |